1.Why do antithrombotic drugs have bleeding risk? A: Thrombosis is caused by blood clotting, and antithrombotic drugs either melt the blood clot or change the clotting ability of blood to make it less likely to clot. In layman’s terms, thrombosis is “clotting” and antithrombotic is “breaking the blood”, so there is a risk of bleeding. Drugs that claim to have no risk of bleeding are definitely not antithrombotic drugs. 2.Can anticoagulant therapy alone be effective? A: Anticoagulation is the prerequisite for all treatments. Its purpose is to prevent or reduce the further spread of thrombosis, to provide the thrombolytic system in the body with the opportunity to dissolve the thrombus, to gain time for the recanalization and repair of blood vessels, and to avoid the recurrence of thrombosis. If you need to enhance the efficacy, you also need to cooperate with thrombolytic therapy, endovascular treatment or surgery. 3.Why do we need to check a lot of blood to treat DVT? A: The etiology of DVT is complex, and some etiologies determine the length of treatment. In addition, antithrombotic drugs have the risk of bleeding, and coagulation function needs to be checked as appropriate to reduce the occurrence of bleeding. In addition, some thrombotic markers can reflect the changes of the disease. Therefore, blood tests need to be drawn frequently during treatment. 4.What are the advantages and disadvantages of thrombolytic therapy? A: The advantages of thrombolytic therapy are that it can accelerate the dissolution of thrombus, reduce vascular damage and enhance the long-term effect. Moreover, the contemporary minimally invasive surgery is more effective when the catheter enters the thrombus directly for thrombolysis treatment. However, thrombolytic therapy also has some disadvantages: (1) increased risk of bleeding; (2) increased cost; (3) catheter-directed thrombolysis requires lowering the vena cava filter and, if necessary, stenting to resolve iliac vein stenosis, which results in high treatment cost. 5.Which patients are at high risk for anticoagulation thrombolytic therapy? A: These patients include: (1) recent history of major surgery or major trauma; (2) bleeding disorders; (3) recent cerebral infarction or cerebral hemorrhage; (4) recent history of central nervous system surgery; (5) recent history of central nervous system trauma; (6) unstable control of hypertension; (7) active peptic ulcer (gastric ulcer and duodenal ulcer); (8) severe liver and kidney function (9) the need for high doses of antiplatelet drugs. 6.Can anti-platelet drugs treat deep vein thrombosis? A: There is no clear basis for antiplatelet drugs to treat deep vein thrombosis. 7.Can blood-stasis-activating drugs treat deep vein thrombosis? A: There is no clear anticoagulation effect of blood-stasis-activating drugs, only partial anti-platelet effect and improvement of blood viscosity, which is far from the concept of regular anticoagulation treatment, not to mention the thrombolytic effect. Most of the efficacy studies of these drugs take the improvement of lower limb edema as the efficacy standard, which is very unscientific and cannot reflect whether the thrombus disappears.